Betahistine in the treatment of Ménière’s disease by Lacour, Michel et al.
Neuropsychiatric Disease and Treatment 2007:3(4) 429–440
© 2007 Dove Medical Press Limited. All rights reserved
429
EXPERT OPINION
Betahistine in the treatment of Ménière’s disease
Michel Lacour1
Paul H van de Heyning2 
Miroslav Novotny3 
Brahim Tighilet1
1UMR 6149 Université de Provence/
CNRS “Neurobiologie Intégrative 
et Adaptative”, Marseille Cedex 3, 
France; 2University Department 
of Otorhinolaryngology. Antwerp 
University Hopsital, Antwerp, Belgium; 
3ENT Clinic, Faculty Hospital, Brno, 
Czech Republic
Correspondence: Michel Lacour
UMR 6149 Université de Provence/CNRS 
“Neurobiologie Intégrative et Adaptative” 
– Pôle 3C, Comportement, Cerveau, 
Cognition, Centre de St Charles, Case 
B. 3, Place Victor Hugo, 13331 Marseille 
Cedex 3, France
Email Michel.Lacour@up.univ-mrs.fr
Abstract: Ménière’s disease and related disease of the vestibular system are common and 
debilitating. Current therapy is multi-modal and includes drug therapy and lifestyle adaptations. 
Unfortunately many of the drugs used in treatment (particularly those used to control nausea) 
are sedative and hamper the process of vestibular compensation. Although betahistine (Serc®, 
BetaSerc®; Solvay Pharmaceuticals) is the mainstay of drug treatment in these illnesses, its 
efﬁ  cacy has not, until recently, been evaluated to modern standards. Betahistine is an analog of 
histamine with weak agonist properties at histamine H1 receptors and more potent anatgonistic 
effects at histamine H3 receptors. Growing evidence suggests that the mechanism of action 
of betahistine lies in the central nervous system and in particularly in the neuronal systems 
involved in the recovery from process after vestibular loss. The histaminergic neurones of the 
tuberomamillary and vestibular nuclei are implicated. In recent years the clinical efﬁ  cacy of 
betahistine has been demonstrated in double-blind, randomized, placebo, and active controlled 
studies in adequate numbers of patients. Although the results of comparative studies between 
betahistine and other drugs (ﬂ  unarizine, cinnarizine, and cinnarizine + dimenhydrate) are 
equivocal, the efﬁ  cacy of betahistine is now clear.
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Introduction
Ménière’s disease is an illness in which multi-modal treatment is the norm. Lifestyle 
changes, physical therapy, vestibular adaptation, drug therapy, and ablative and non-
ablative surgery are all options in its treatment and are frequently used in combina-
tion. Among all of the drug therapies used, betahistine (Serc®, BetaSerc®; Solvay 
Pharmaceuticals) is the most frequently chosen in Europe; in a recent survey, 94% of 
physicians in the UK prescribe betahistine for Ménière’s disease (Smith et al 2005) 
and the drug has been employed in the treatment of Ménière’s disease and vertigo 
of peripheral vestibular origin for more than 40 years. However, until recently, the 
efﬁ  cacy of this drug had not been evaluated to modern standards and its mechanism 
of action remained obscure. The objective of this review is to evaluate the evidence 
for the efﬁ  cacy of betahistine in Ménière’s disease and examine the latest evidence 
on its mechanism of action.
Ménière’s disease
Deﬁ  nition
Ménière’s disease comprises recurrent spontaneous episodes of rotatory vertigo spells 
that patients describe as a spinning or whirling feeling and sensorineural hearing loss 
(SNHL) accompanied by recruitment and tinnitus. An unpleasant sensation of aural 
fullness on the affected side may also occur (Van de Heyning et al 2005). Ménière’s 
disease is also called idiopathic endolymphatic hydrops (ELH), a term which describes 
a disorder of the inner ear in which there is a build-up of endolymph (AAO-HNS 1995). 
Of the various symptoms of Ménière’s disease, vertigo is usually the most trouble-
some, at least in the acute phase, due to its unpredictable nature (Cohen et al 1995; Neuropsychiatric Disease and Treatment 2007:3(4) 430
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Kentala 1996). Vertigo spells can last from several minutes to 
several days and are frequently debilitating. Anxiety, depres-
sion, and space and motion disorder (an inability to orientate 
oneself and the difﬁ  culties encountered in large spaces or by 
moving surroundings) often develop (Anderson and Harris 
2001). During vertigo attacks, patients are quite unable to 
undertake normal work or social activities. Nausea is com-
mon and patients may vomit during an attack. Sleepiness 
may follow for several hours, and an off-balance sensation 
may last for a number of days. Quality of life is frequently 
seriously diminished (Cohen et al 1995). During later stages 
of the disease, hearing loss, sound distortion, recruitment, and 
tinnitus further affect quality of life (Kinney et al 1997).
Epidemiology
Together with back pain and headaches, dizziness and vertigo 
are among the most common symptoms causing patients 
to visit their physician. For example, a community survey 
among 50- to 60-year-olds revealed that a quarter currently 
suffered from giddiness or dizziness (Stephens et al 1990, 
1991). Such problems tend to become more common and 
more severe with age, so that by age 80 years, up to two-
thirds of women and one third of men will have experienced 
episodes of vertigo. (Luxon 1984). Ménière’s disease is a 
common cause of dizziness and vertigo spells. In most cases 
only one ear is involved, but both ears may be affected in 
about one third of patients. If both ears are affected, the 
disease generally starts in the second ear within the ﬁ  ve ﬁ  rst 
years of onset of the ﬁ  rst ear. Ménière’s disease typically 
starts between the ages of 20 and 50 years, a diagnosis rate 
that increases with age up to 60 years (Wladislavosky et al 
1980). Men and women are equally affected.
There is considerable disagreement in the world literature 
about the incidence and prevalence of Ménière’s disease 
with estimates varying by as much as a factor of 10 from 
country to country. Ranges of prevalence vary from over 
200 cases/100,000 in the USA (with an incidence of over 
15 cases/100,000 persons/year) (Cawthorne and Hewlett 
1954) to prevalences as low as fewer than 20/100,000 in 
Japan (Wanatabe et al 1995; Shojaku and Watanabe 1997), 
with a prevalence level of about 46/100,000 in Scandinavia 
(Stahle et al 1978; Kotimaki et al 1999), making Ménière’s 
disease four times more common than otosclerosis. Although 
vertigo symptoms may decline with time leading to a “burn-
out” of the inner ear, Havia and Kentala (2004) have shown 
a progression of the intensity of the vertigo symptoms during 
the longitudinal course of Ménière’s disease. In a prospec-
tive study of 243 consecutive patients admitted to their 
hospital, they found that the proportion of patients reporting 
severe or very severe attacks increased with the duration of 
symptoms. Nausea was also more common later in the disease 
than at the beginning. Sudden falls due to otolythic crisis 
(Tumarkin 1936) may arise many years after the last vertigo 
spell. Up to 25% of patients with Ménière’s disease may 
eventually require a surgical procedure to control the vertigo 
attacks (Filipo and Barbara 1977). Overall this suggests that 
untreated Ménière’s disease worsens over time.
Pathophysiology
Although the underlying cause of Ménière’s disease remains 
obscure and ELH is one of the common ﬁ  nal physiopatholog-
ical responses of the inner ear to many factors (Kiang 1990), 
Ménière’s disease nevertheless results from an abnormality 
in the ﬂ  uid homeostasis of the inner ear (Andrews 2004). The 
proposed two phase model in which there is an imbalance 
between endolymph production and resorption (Dunnebier 
et al 1997, 2002) leading to volume expansion without pres-
sure increase (Warmerdam et al 2003), is complemented 
with round membrane characteristics (Feijen et al 2004), 
perilymphatic regulating mechanisms (Laurens-Thalen et al 
2004), and aquaporin involvement.
With the increase of ELH, there is a risk of a rupture in 
the membranous labyrinth, with the consequent mixing of 
endolymph and perilymph. The changing levels of potassium 
are presumed to give rise to the vestibular symptoms. The 
rupture of the membrane with hydrops is thought to explain 
the amelioration of the cochlear symptoms when vertigo 
appears. The repetition of hydrops crises and repeated rupture 
of the membrane are thought, in turn, to be responsible for the 
progressive destruction of the labyrinth and give rise to the 
evolution of profound deafness and disappearance of vertigo. 
Although the evidence for ELH as the pathophysiological 
basis of Ménière’s disease is well supported by scientiﬁ  c 
evidence, there is also evidence to suggest that it is not the 
only mechanism (Merchant et al 2005). For instance gangli-
onitis has been reported to contribute to Ménière’s disease 
(Selamani et al 2005).
Therapeutic management
Acute treatment
The ﬁ  rst goal in the acute phase is to symptomatically control 
the vertigo spells by stopping the rotational sensation and 
accompanying nausea and neurovegetative symptoms. Drug 
treatment with anti-emetics (eg, domperidone), vestibuloseda-
tive anti-histamines (eg, meclizine), and central sedative drugs 
with vestibulo-suppressive or anti-emetic effect (eg, diazepam, Neuropsychiatric Disease and Treatment 2007:3(4) 431
Betahistine for Ménière’s disease
sulpiride, dihydrobenzperidol, and phenothiazine) are useful 
during this phase of treatment. Nausea and vomiting frequently 
require that such drugs are given by intra-rectal or parenteral 
routes. Although widely used, there is little evidence to guide 
the physician in choosing one of these medications over 
another for a particular patient.
Long-term treatment
Long-term treatment has as its goal to prevent or diminish 
further spells of vertigo, to assist the patient with compensa-
tion for the vestibular deﬁ  cit, to ameliorate or assist with the 
hearing loss and associated symptoms. Treatment modalities 
will include counselling, life style adaptation, drug therapy, 
rehabilitation, and surgery according to the stage and pro-
gression of the illness
Because of the uncertainties of the illness, counseling is 
required for all patients. General life style adaptations consist 
of salt restriction and avoidance of caffeine, alcohol, tobacco, 
and coping with stress. Patients can frequently identify an 
event that provokes attacks and can be counseled to avoid 
such situations.
Chronic drug therapy
Drug therapy can play an important role in the treatment of 
most Ménière’s disease patients (for overview: Claes and Van 
de Heyning 1997, 2000). Betahistine is of beneﬁ  t and, unlike 
sedative alternatives, does not interfere with the development 
of vestibular compensation. Diuretics can also be of beneﬁ  t 
(Klockhoff and Lindblom 1967; Van Deelen and Huizing 
1986), although the use of acetazolamide in Ménière’s dis-
ease is still controversial. When the transition from acute to 
chronic treatment fails to alleviate symptoms, mild vestibular 
sedatives such as cinnarizine may be of help.
Where an inflammatory component is suspected in 
bilateral Ménière’s disease, short courses of systemic 
glucocorticoids may be appropriate. It recently has been 
shown that glucocorticoids not only inﬂ  uence inﬂ  ammatory 
process in Ménière’s disease, but also alter ﬂ  uid dynamics 
via an interaction with the sodium pumps in the semicircular 
canals (Ponduglula et al 2004). Intra-tympanic application 
of corticosteroids appears to have only temporary effects 
(Dodson 2004) and is probably not recommended (Doyle 
et al 2004).
Anti-depressive treatment (eg, selective serotonin 
reuptake inhibitors) may improve the psychological 
handicap aspect of vertigo in pre-existing depression, but 
is of no beneﬁ  t to vertigo itself nor in patients without pre-
existing depression (Horii et al 2004). Where anxiety and 
stress susceptibility exacerbate the condition, short courses 
of benzodiazepines (eg, alprazolam or serenase) can be 
administered, but dependence is a concern during the longer 
term.
Vestibular rehabilitation 
Vestibular rehabilitative therapy is useful for central 
vestibular compensation of peripheral vestibular asymmetry 
and consequent motion intolerance. Evidence is accumulating 
that Ménière’s disease patients can beneﬁ  t from this therapy 
with a general or customized training program (Clendaniel 
and Tucci 1997; Dowdol-Ostorn 2002). When choosing drug 
therapy it is important to consider its effect on vestibular 
compensation; sedative drugs can seriously impair the 
process and are to be avoided if at all possible.
Betahistine 
Mechanism of action
Histamine (HA) is a neuromodulatory transmitter that 
regulates various cerebral functions (wakefulness: Lin 1994; 
cardio-vascular regulation: Laurikainen et al 1993, 1998). 
In mammals, the histaminergic neurons are exclusively 
located in the tuberomammillary (TM) nuclei of the 
posterior hypothalamus (Pollard and Schwartz 1987) but 
the histaminergic nerve endings show a wide distribution 
throughout the whole brain. Three types of HA receptors 
have been identiﬁ  ed: the postsynaptic histamine H1 and H2 
receptors (Schwartz 1979) and the presynaptic histamine H3 
receptors (Arrang et al 1983; Schwartz et al 1990). HA and 
histamine H3 receptor agonists inhibit HA turnover while 
HA receptor antagonists increase HA turnover and release 
in the central nervous system (CNS). The HA-containing 
perikarya of the TM nuclei send axonal projections to the 
whole vestibular nuclei (VN) complex in many species 
(Airaksinen and Panula 1988: guinea pig; Panula et al 
1989: rat; Tighilet and Lacour 1996: cat). In addition, all 
three categories of HA receptors are present in the VN and 
reciprocal connections between the VN and the TM nuclei 
are supported by electrophysiological (Horii et al 1993), 
immunohistochemical (Tighilet et al 2006), molecular 
(Gustave dit Duﬂ  o et al 1999, 2000), and behavioral (Takeda 
et al 1987) investigations. Taken together, the data strongly 
suggest that HA regulates also the vestibular functions (see 
Lacour and Sterkers 2001 for a review). Indeed, HA modula-
tion of second-order vestibular neurons was found both in 
vitro (Jaju and Wang 1971) and in vivo (Phelan et al 1990; 
Inverarity et al 1993; Seraﬁ  n et al 1993) preparations. More-
over, chronic infusion of HA receptor ligands in the VN on Neuropsychiatric Disease and Treatment 2007:3(4) 432
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one side induces behavioral modiﬁ  cations (Yabe et al 1993). 
Postural and oculomotor deﬁ  cits similar to those seen after a 
unilateral vestibular loss were found following H2 receptor 
antagonists or H3 receptor agonists perfusion whereas the 
vestibular syndrome was reversed after local administration 
of H2 receptor agonists or H3 receptor antagonists.
Betahistine in vestibular disorders
Betahistine dihydrochloride is one of the drugs currently 
prescribed in patients with vestibular loss for their symp-
tomatic treatment of vertigo, and especially in Ménière’s 
patients (Rascol et al 1995). It is a structural analog of HA 
with weak histamine H1 receptor agonist and more potent 
histamine H3 receptor antagonist properties (Arrang et al 
1985; Timmerman 1991). Some sites of action of betahistine 
are known since a long time while new basic mechanisms 
at the CNS level were elucidated in a recent past only (see 
Lacour and Sterkers 2001).
Peripheral mechanisms
Until recently, it was generally believed that the efﬁ  cacy 
of betahistine was due to vascular mechanisms in the 
inner ear. Increase in cochlear blood ﬂ  ow was reported 
after systemic administration of betahistine (Meyer et al 
1974; Laurikainen et al 1993, 1998). The authors found 
that betahistine antagonizes the H3 heteroreceptors of the 
cochleo-vestibular vascular tree through the activation of 
autonomic alpha-2 receptors. Vasodilatation of the anterior 
inferior cerebellar artery could be involved, suggesting that 
the betahistine-induced increase in cochlear blood ﬂ  ow was 
associated with an increase in vascular conductivity and a 
decrease in systemic blood pressure. This effect appears to 
involve histamine H1 receptors, histamine presynaptic H3 
heteroreceptors, and autonomic alpha-2 receptors, at least in 
the guinea pig inner ear.
Another peripheral mechanism was recently put forward 
by Botta et al (1998) in the frog. The authors examined 
the effects of betahistine on isolated preparations of frog 
posterior semicircular canals and found a decrease of the 
resting discharge of the ampullar receptors when the drug 
was administrated via the perilymphatic ﬂ  uid. The effect 
could involve HA receptors in the peripheral vestibular 
system, a mechanism that remains, however, to be conﬁ  rmed. 
More recently, H3 antagonists such as thioperamide and 
betahistine were found to decrease the electrical discharge 
of afferents neurons in the axolotl by interfering with the 
postsynaptic response to excitatory amino acid agonists 
(Chavez et al 2005). The results support the idea that 
antivertigo action of HA-released drugs may be caused, 
at least in part, by a decrease in the sensory input from the 
vestibular endorgans.
Whatever the real nature of the mechanism elicitated at 
the peripheral level after administration of betahistine, it 
seems that it contributes, at least partly, to the antivertigo 
property of the drug.
Central mechanisms
There is today a growing body of data indicating that HA acts 
also on central neuronal networks involved in the recovery 
process after vestibular loss (Lacour and Sterkers 2001), 
and that betahistine-induced improvements in vestibular 
disorders and vertigo result from such central effects at 
various CNS levels.
It has clearly been shown that the behavioral recovery 
process after unilateral vestibular neurectomy (UVN) in 
the cat is strongly accelerated under betahistine treatment 
(Tighilet et al 1995). Betahistine treatment reduces the time 
to recovery by 2 weeks for both static (posture) and kinetic 
(locomotor equilibrium) functions compared with controls 
(untreated and double blind, placebo-controlled animals 
(Figure 1). Immunohistochemical investigations performed 
in the same cat model suggest that improvement in vestibular 
compensation is related to changes in HA synthesis and release 
(Tighilet and Lacour 1997). Further studies using an in situ 
hybridization method for quantifying the messenger RNA for 
histidine decarboxylase (HDC), the enzyme synthesizing HA, 
pointed to an up-regulation of HDC mRNA in the TM nuclei of 
cats treated with HA-like drugs (Tighilet et al 2002) (Figure 2). 
In addition, receptor binding studies showed a downregulation 
of histamine H3 receptors in both the VN and TM nuclei. It 
seems very likely, therefore, that betahistine upregulates HA 
turnover by blocking the presynaptic histamine H3 receptors. 
This hypothesis is corroborated by the well known role of 
these receptors in mediating autoinhibition of brain HA release 
(Arrang et al 1983) and autoregulation of HA synthesis (Arrang 
et al 1987, 1992). In rat brain slices, agonists and antagonists 
of the histamine H3 receptors reduce and enhance HA release, 
respectively (Arrang et al 1983, 1987; Garbag et al 1989). 
The VN are known to play a crucial role in the recovery 
process after vestibular lesion (Lacour et al 1989; Smith 
and Curthoys 1989) and are involved in an histaminergic 
vestibulo-hypothalamo-vestibular loop. It has been 
demonstrated recently that this histaminergic loop was 
implicated in the adaptive response to vestibular lesion 
(Tighilet et al 2006). HDC mRNA expression was: 
up-regulated in the ipsilateral TM nucleus in UVN cats; up-Neuropsychiatric Disease and Treatment 2007:3(4) 433
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regulated in the contralateral TM nucleus in compensated 
UVN cats submitted to a second vestibular nerve section on 
their intact side (two steps bilateral vestibular neurectomy); 
and unchanged in one step bilateral vestibular neurectomized 
cats. The effectiveness of betahistine in the treatment of 
vertigo and vestibular disease can be seen therefore by the 
effects of HA release on second-order vestibular neurons. HA 
depolarizes the medial VN cells in vitro in rats (Phelan et al 
1990; Inverarity et al 1993) and guinea pigs (Séraﬁ  n et al 1993; 
Wang and Dutia 1995). The VN control the vestibulo-ocular 
and vestibulo-spinal reﬂ  exes (Wilson and Melvill Jones 1979; 
Lacour and Borel 1993) and plays a major role in gaze stabili-
zation, a function that is strongly impaired after vestibular loss 
and alteration of the peripheral vestibular system.
Antihistamines have been found effective in vertigo treat-
ment probably due to central depressive effects. HA (Fischer 
1991) and HA-like drugs such as betahistine dihydrochloride 
have been used also as antivertigo agents for over 20 years 
(see Rascol et al 1995 for a review). A major advantage of 
betahistine is that no sedative effects were observed following 
its administration in animal models (Lin 1994) or in healthy 
subjects (Betts et al 1991). On the contrary, HA-induced 
excitatory effects on the neuronal activity of cortical and 
subcortical structures in the cat by activating histamine H1 
receptors (Lin 1994). These other central targets of HA very 
likely participate to the restoration of vestibular functions, 
indirectly. Indeed, brain arousal facilitates sensorimotor 
activity, a factor that was found crucial for the recovery 
process after vestibular loss in the cat (Xerri and Lacour 
1980; Lacour et al 1989).
Finally, a dose-dependent and duration-dependent effect 
of betahistine treatment on HA turnover in the cat has been 
reported (Tighilet et al 2005). With a low dose (2 mg/kg) 
given over a long time period (3 months), similar to the dos-
ing used clinically and reported to have anti-vertigo effects 
(Oosterveld et al 1987; Constantinescu et al 1996; Kingma 
et al 1997), HA synthesis and release were signiﬁ  cantly 
increased in our animal model. The data are in favor of 
symptomatic treatment of vertigo in humans by means of 
HA-like drugs.
Clinical efﬁ  cacy
Over the years, betahistine has acquired a dominant position 
in the pharmacotherapeutic armamentarium for Ménière’s 
disease and other disorders of the inner ear. It is associated 
with the beneﬁ  cial effects of histamine, but, unlike histamine, 
is does not cause headaches, ﬂ  ushing, blurred vision, vomit-
ing, or sedation. Thus patients whose Ménière’s disease is 
Figure 1 Mean recovery curves illustrating maximal performance of the cat on the rotating beam. Results are expressed in percent of the preoperative maximal 
performance (on the ordinates) as a function of the postoperative time in days (on the abscissae). The betahistine groups (50 mg/kg and 100 mg/kg) are shown as solid 
squares and triangles, respectively, and the control group as open circles. Standard errors of the mean are shown as vertical lines. Note the acceleration of the recovery 
time under betahistine treatment compared with the controls, and the shortened time required to achieve a full compensation (3 weeks instead of 6 weeks).
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controlled by betahistine can maintain their lifestyles without 
fear of fall and fractures, and, most importantly betahistine 
does not interfere with vestibular rehabilitation.
Betahistine has been widely used for management of a 
range of disorders including Ménière’s disease vertigo of 
various origin and tinnitus, with good results and widespread 
acceptance by physicians for many years. However, until 
relatively recently this widespread use was not based fully 
supported by modern standards of evidence based medicine. 
However, in recent years a number of high-quality studies 
have been completed which better conﬁ  rm the efﬁ  cacy 
of betahistine in Ménière’s disease. The time is therefore 
opportune to review the evidence base for betahistine.
Clinical studies on betahistine up to the year 2000 have 
been reviewed by Mira (2001). In this period there were 
more than 20 controlled clinical studies of betahistine 
and, while none could be considered methodologically 
flawless, taken together they strongly suggest that 
betahistine is effective in reducing the frequency, 
severity and duration of vertigo and possibly neurovegi-
tative symptoms in vertigo of various aetiologies, but 
particularly in Ménière’s disease. It is also apparent that 
tinnitus and hearing loss are far less amenable to treatment 
with betahistine. In addition to these clinical efficacy 
studies, laboratory studies on patients with vertigo have 
also yielded interesting results; a dose-dependent effect 
of betahistine on the vestibulo-ocular reflex was demon-
strated (Kingma et al 1997) in paroxysmal vertigo patients 
who had previously responded to betahistine.
Comparative studies with betahstine during the early 
years of its investigation suggested that it was less effec-
tive than trimetazidine (Kluyskens et al 1990; Martini and 
De Domenico 1990), and ﬂ  unarizine (Elbaz 1988) (though 
this has been challenged in later studies [Albera et al 2003]) 
and at least as effective as cinnarizine (Deering et al 1986) 
and prochlorperazine (Aantaa and Skinhoj 1976). However, 
few of these studies are altogether convincing and fewer 
still have been replicated.
Betahistine continued to be used in many territories on 
this less than ideal evidence base for many years, although 
the Food and Drug Administration were unconvinced by the 
data and withdrew the drug’s licence. It remains unlicensed 
in the US, although widely available elsewhere and anecdotal 
evidence suggests that patients in the US frequently obtain 
the drugs overseas.
More robust clinical evidence is available from recent 
clinical trials and the remainder of this review will focus on 
these studies, some very recent and others as yet unpublished. 
Figure 2 Quantiﬁ  cation of the histidine decarboxylase (HDC) mRNA labeled surface in the right (hatched columns) and left (solid columns) tuberomammillary (TM) nuclei 
for the two groups of betahistine-treated cats compared with the control, untreated cats (open columns). Note that HDC mRNA labeled surface is signiﬁ  cantly increased in 
the TM nuclei of betahistine-treated cats. ** p < 0.0001. 
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These studies are evaluated below and summarized in 
Table 1.
Placebo-controlled trials
In a double-blind, parallel group study undertaken at 11 
centers in Italy, a total of 144 patients with peripheral 
vestibular vertigo (including Meniere’s disease and 
paroxyxsmal peripheral vertigo of suspected vascular origin) 
were randomized to receive either placebo or betahistine 8 
mg twice daily for up to 3 months (Mira et al 2003). Efﬁ  cacy 
was determined by the frequency, severity and duration of 
vertigo attacks, the GISFaV self-rating scale and Dizziness 
Handicap Inventory (DHI). After 3 months of treatment the 
mean frequency of vertigo attacks was reduced from 6.7 per 
month at baseline to 2.06 per month in Meniere’s disease 
patients and from 6.9 per month to 1.91 per month in PPV 
patients. The difference between betahistine and placebo 
was signiﬁ  cant from the end of the ﬁ  rst month’s treatment 
onwards (Figure 3 and Figure 4). The vertigo intensity 
score was more frequently improved on betahistine than 
on placebo, a difference that was signiﬁ  cant from day 15 
onwards and associated symptoms (tinnitus, aural fullness, 
nausea, and vomiting was also more frequently improved on 
betahistine than on placebo. GISFaV scores improved in 70% 
of betahisitine patients, but in only 30% of the placebo group, 
moreover, the proportion of patients GISFaV of zero at 3 
months was 57% in the betahistine-treated patients compared 
to 3% in those given placebo. Similarly the six of the seven 
items in the Dizziness Assessment Rating Scale were 
improved more by betahistine than by placebo. Betahistine 
signiﬁ  cantly reduced DHI scores signiﬁ  cantly more freqently 
than placebo. The physican’s rating of treatment was good or 
very good in 74% of betahistine-treated patients compared 
with 27% of placebo-treated patients.
Comparative studies
Dizziness Handicap Score was used as the primary efﬁ  cacy 
variable in a study by Albera and colleagues (Albera et al 
2003). Seventy-eight patients who were severely handicapped 
vertigo of peripheral vestibular origin were randomized to 
receive 8 weeks treatment with either betahistine 16 mg 
tid or ﬂ  unarizine 10 mg od. Although DHI score decreased 
signiﬁ  cantly in both groups during treatment, the decrease 
on betahistine treatment was signiﬁ  cantly greater than 
that on ﬂ  unarizine (decrease from baseline of 12.4 for 
betahistine vs 8.8 for ﬂ  unarizine , p < 0.01). Vegetative 
symptoms (of which nausea was the most common) 
decreased signiﬁ  cantly in both groups, without signiﬁ  cant 
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difference between the treatments. Tinnitus was the most 
refractory symptom with no signiﬁ  cant reduction by either 
treatment. Betahistine also appeared to be somewhat 
quicker in reducing the handicap associated with vertigo. 
Although there was no signiﬁ  cant difference between the 
treatments in their reduction of vegetative symptoms, it was 
the physical (rather than functional or emotional) subscores 
of the DHI that showed the greatest difference between 
betahistine and ﬂ  unarizine (5.7 vs 6.0 for betahistine and 
ﬂ  unarizine respectivly, p < 0.01). Moreover, there was a 
clear relationship between the improvement of DHI scores 
and the improvement in vegetative symptoms.
Figure 3  Percentage improvement in frequency of vertigo attacks – Menière’s disease. Reproduced with permission from Mira E, Guidetti G, Ghilardi L, et al 2003. Betahis-
tine dihydrochloride in the treatment of peripheral vestibular vertigo. Eur Arch Otorhinolaryngol, 260:73–7. Copyright © 2003 Springer. 
Figure 4 Percentage improvement in frequency of vertigo attacks – peripheral paroxysmal vertigo. Reproduced with permission from Mira E, Guidetti G, Ghilardi L, et al 
2003. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. Eur Arch Otorhinolaryngol, 260:73–7. Copyright © 2003 Springer.
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Betahistine for Ménière’s disease
An earlier study by Fraysse and colleagues (Fraysse et al 
1991) yielded similar results. In this multicenter, double-blind, 
randomized trial, in which 55 patients received either 
betahistine 48 mg/day or ﬂ  unarizine 10 mg/day, betahistine 
was signiﬁ  cantly superior to ﬂ  unarizine for frequency and 
duration of vertigo attacks and the presence of vegetative 
symptoms. The results of these two studies are in contrast to 
an earlier 2-month double-blind comparison of betahistine 8 
mg tid and ﬂ  unarizine 10 mg od in 117 patients with vestibular 
vertigo, which found ﬂ  unarizine to be signiﬁ  cantly superior 
to betahistine. It is not clear to what extent the lower dose of 
betahistine used in this study might have contributed to the 
lack of efﬁ  cacy that was observed.
Two studies have compared betahistine with the 
ﬁ  xed combination of cinnarizine and dimenhydrinate. In 
the ﬁ  rst study by Novotny and Kostrica (2002), patients 
with Méniere’s disease were entered into a randomized, 
double-blind, parallel group study lasting 12 weeks. 
Eighty-two patients were randomized to treatment with 
betahistine 12 mg tid or cinnarizine plus dimendydrinate. 
The intensity of vertigo, as measured by the patient on 
a visual analogue scale was markedly reduced by both 
treatments from a baseline score of 2.4–0.31 and 0.4 
for betahistine and cinnarizine plus dimendydrinate, 
respectively, there was no statistically significant 
difference between the two treatments. Tinnitus and 
vegetative symptoms were also significantly, and 
approximately equally, reduced by the two treatments.
Betahistine was used as a reference therapy in the 
study of a new fixed combination of cinnarizine 20 mg 
plus dimenhydrinate 40 mg in patients with vertigo of 
peripheral vestibular origin (Cirek et al 2005). Sixty-one 
patients were entered into the single center study and 
were randomized to 4 weeks of treatment with betahistine 
12 mg or cinnarizine plus dimenhydrinate. Both betahis-
tine and cinnarizine plus dimenhydrinate reduced mean 
vertigo scores, although cinnarizine plus dimenhydrinate 
was significantly more effective than betahistine. Vertigo-
associated symptoms were also reduced more effectively 
by cinnarizine plus dimenhydrinate than by betahistine.
Open studies
The efficacy of betahistine has also been confirmed in 
open naturalistic studies. An as yet unpublished study by 
Novotny and Kostrica (2002) found symptoms disappeared 
or improved in 93% (15% and 78% respectively) of 293 
patients with Ménière’s disease of at least 3 months duration 
who were treated with betahistine 16 mg tid.
Safety and tolerability
Adverse events appear to be rare during betahistine therapy, 
mild skin reactions are the most common and epigastric 
upset is reported occasionally as is headache and nausea 
(the latter also a symptom of the illness being treated). 
Although formal safety and tolerability studies have not 
been undertaken to modern standards the drug has been 
used for many decades and tens of millions of patients 
have been exposed without signiﬁ  cant safety or tolerability 
concerns having arisen.
Discussion
Ménière’s is a relatively common and debilitating otological 
condition. Whilst many drug therapies are employed, the great 
majority hamper vestibular adaptation and, whilst reducing 
the distressing symptoms of vertigo, may hinder long-term 
recovery. Betahistine has been a staple of the treatment of 
Ménière’s disease and other disorders that include vertigo 
as a cardinal symptom. Until recently however, evidence 
for its efﬁ  cacy has not been available to modern standards 
of proof. The past 10 years have seen signiﬁ  cant advances, 
not only in clarifying the efﬁ  cacy of betahistine, but also in 
our understanding of its mechanism of action – a remarkable 
situation for a drug that has been in routine clinical use for 
more than 40 years.
Besides vascular action in the inner ear, modulation of 
the peripheral vestibular sensory cells, and excitatory effect 
on the neuronal activity of cortical and subcortical structures, 
betahistine interacts strongly with the histaminergic 
system increasing histamine synthesis and release in the 
tuberomammillary nuclei of the posterior hypothalamus. The 
action of histamine on the vestibular cells on the affected side 
may contribute to a rebalancing of neuronal activity between 
the two sides; a key mechanism in the vestibular recovery 
process. Vestibular deﬁ  cits require a considerable period 
for compensation to occur and these long-term adaptive 
mechanisms can be facilitated pharmacologically using 
histaminergic-like drugs such as betahistine. Animal studies 
show clearly that betahistine does not interfere with vestibular 
adaptation in the way that drugs with sedative effects do.
The situation concerning the clinical efficacy of 
betahistine is now somewhat regularized in that random-
ized placebo and active controlled clinical trials have 
confirmed that betahistine is effective in the treatment 
of Ménière’s disease and related conditions. However, 
compared with modern standards of evidence-based 
medicine, further trials, randomized, placebo-controlled 
studies in particular, would be welcome. Nevertheless, Neuropsychiatric Disease and Treatment 2007:3(4) 438
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the available data from recent well-conducted trials 
shows that betahistine is more effective than placebo or 
flunarizine. Comparative studies of betahistine with the 
fixed combination of cinnarizine and dimenhydrinate are 
equivocal, whilst there are clear and significant reductions 
in symptoms with both treatments, their relative efficacy 
is not clear. More studies are needed, but it is now clear 
that betahistine is effective in Ménière’s disease – after 
40 years of clinical use it would have been surprising 
if this were not the case – its freedom from sedative 
properties that interfere with vestibular adaptation is 
a major clinical advantage compared with many drugs 
employed in this field.
Although it remains true that there is still much to learn 
about betahistine, important advances have been in made in 
understanding its place in the therapy of Ménière’s disease 
and related illnesses and in elucidating its mechanism of 
action.
References
Aantaa E, Skinhoj A. 1976. Controlled clinical trial comparing the effect 
of betahistine hydrochloride and prochlorperazine maleate on patients 
with Ménière’s disease. Ann Clin Res, 8:284–7.
AAO-HNS. Committee on hearing and equilibrium. 1995. Guidelines for the 
diagnosis and evaluation of therapy in Ménière’s disease. Otolaryngol 
Head Neck Surg, 113:181–5.
Airaksinen MS, Panula P. 1988. The histaminergic system in the 
guinea pig central nervous system: an immunocytochemical map-
ping study using an antiserum against histamine. J Comp Neurol, 
273:163–6.
Albera R, Ciuffolotti R, Di Cicco M, et al. 2003. Double-blind, randomized, 
multicenter study comparing the effect of betahistine and ﬂ  unarizine 
on the dizziness handicap in patients with recurrent vestibular vertigo. 
Acta Otolaryngol, 123:588–93.
Allum JHJ, Keshner EA, Honegger F, et al. 1988. Indicators of the 
influence a peripheral vestibular deficit has on vestibulo-spinal 
reflex responses controlling postural stability. Acta Otolaryngol, 
106:252–63.
Anderson JP, Harris JP. 2001. Impact of Ménière’s disease on quality of 
life. Otol Neurotol, 22:888–94.
Andrews JC. 2004. Intralabyrinthine ﬂ  uid dynamics: Meniere disease. Curr 
Opin Otolaryngol Head Neck Surg,12:408–12.
Arrang JM, Garbag M, Quatch TT, et al. 1985. Actions of betahistine at 
histamine receptors in the brain. Eur J Pharmacol, 111:73–84.
Arrang JM, Garbag M, Schwartz JC. 1987. Autoregulation of histamine 
synthesis in brain mediated by presynaptic H3 receptors. Neuroscience, 
23:149–57.
Arrang JM, Garbarg M, Schwartz JC. 1983. Auto-inhibition of brain his-
tamine release mediated by a novel class H3. of histamine receptor. 
Nature, 302:832–7.
Arrang JM, Garbag M, Schwartz JC. 1992. H3-receptors and control 
of histamine release. In Schwartz JC, Haas HL eds. The histamine 
receptors. New York: Wiley-Liss. 145–60.
Betts T, Harris D, Gadd E. 1991. The effects of two antivertigo drugs 
betahistine and prochlorperazine. on driving skills. Br J Clin 
Pharmacol, 32:455–8.
Borel L, Harlay F, Lopez C, et al. 2004. Walking performance of vestibular-
defective patients before and after unilateral vestibular neurotomy. 
Behav Brain Res, 150:191–200.
Borel L, Harlay F, Magnan J, et al. 2002. Deﬁ  cits and recovery of head 
and trunk orientations and stabilization after unilateral vestibular loss. 
Brain, 125:880–94.
Botta L, Mira E, Valli S, et al. 1998. Effects of betahistine on vestibular 
receptors of the frog. Acta Otolaryngol, 118:519–23.
Brantberg K, Fransson PA, Bergenius J, et al. 1996. Tilt suppression, OKAN, 
and head-shaking nystagmus at long-term follow-up after unilateral 
vestibular neurectomy. J Vest Res, 6:235–41.
Chávez H, Vega R, Soto E. 2005. Histamine (H3) receptors modulate the 
excitatory amino acid receptor response of the vestibular afferents. 
Brain Res, 7:1–9.
Cirek Z, Schwarz M, Baumann W, et al. 2005. Efﬁ  cacy and tolerability of a 
ﬁ  xed combination of cinnarizine and dimenhydrinate versus betahistine 
in the treatment of otogenic vertigo: a double-blind, randomised clinical 
study. Clin Drug Invest, 26:377–89.
Claes J, Van de Heyning PH. 1997. Medical therapy of Ménière’s disease : 
a review of literature. Acta Otolaryngol Suppl, 526:37–42. 
Claes J, Van de Heyning PH. 2000. A review of medical treatment for 
Meniere’s disease. Acta Otolaryngol Suppl, 544:34–9.
Clendaniel RA, Tucci DL. 1997. Vestibular rehabilitation strategies in 
Meniere’s disease. Otolaryngol Clin North Am, 30:1145-58.
Cohen H, Ewell LR, Jenkins HA. 1995. Disability in Ménière’s disease. 
Arch Otolaryngol Head Neck Surg, 121:29–33.
Constantinescu L, Schneider D, Claussen CF. 1996. The inﬂ  uence of beta-
histine on the vestibular evoked potentials in patients with peripheral 
vestibular disorders. In 3rd EUFOS, Bologna: Monduzzi Editore. 
p. 95–98.
Cawthorne T, Hewlett AB. 1954. Ménière’s disease. Proc R Soc Med, 
47:663–70
Curthoys IS, Dai MJ, Halmagyi GM. 1991. Human ocular torsional posi-
tion before and after unilateral vestibular neurectomy. Exp Brain Res, 
85:218–25.
Dai MJ, Curthoys IS, Hamlagyi GM. 1989. Linear acceleration perception 
in the roll plane before and after unilateral vestibular neurectomy. Exp 
Brain Res, 77:315–28.
Deering RB, Prescott P, Simmons RL, et al. 1986. A double-blind crossover study 
comparing betahistine and cinnarizine in the treatment of recurrent vertigo 
in patients in general practice. Curr Med Res Opin, 10:209–14.
Dodson KM, Sismanis A. 2004. Intratympanic perfusion for the treatment 
of tinnitus. Otolaryngol Clin North Am, 37:991–1000.
Dowdal-Osborn M. 2002. Early vestibular rehabilitation in patients with 
Meniere’s disease. Otolaryngol Clin North Am 35:683–90.
Doyle KJ, Bauch C, Battista R, et al. 2004. Intratympanic steroid treatment: 
a review. Otol Neurotol, 25:1034–9.
Dunnebier EA, Segenhout JM, Wit HP, et al. 1997. Two-phase endolym-
phatic hydrops: a new dynamic guinea pig model. Acta Otolaryngol, 
117:13–19.
Dunnebier EA, Segenhout JM, Dijk F, et al. 2002. Cochlear ultrastructure 
in two-phase endolymphatic hydrops in the guinea-pig. Eur Arch 
Otorhinolaryngol, 259:17–23.
Elbaz P. 1988. Flunarizine and betahistine. Two different therapeutic 
approaches in vertigo compared in a double-blind study. Acta 
Otolaryngol Suppl, 460:143–8.
Feijen RA, Segenhout JM, Albers FW, et al. 2004. Cochlear aqueduct ﬂ  ow 
resistance depends on round window membrane position in guinea pigs. 
J Assoc Res Otolaryngol, 5:404–10.
Filipo R, Barbara M. 1997. Natural history of Méniere´s disease: staging the 
patients or their symptoms? Acta Otolaryngol Suppl, 526:10–13.
Fischer AJ. 1991. Histamine in the treatment of vertigo. Acta Otolaryngol 
Suppl, 479:24–8.
Fraysse B, Bebear JP, Dubreuil C, et al. 1991. Betahistine dihydrochloride 
versus ﬂ  unarizine. A double-blind study on recurrent vertigo with 
or without cochlear syndrome typical of Ménière’s disease. Acta 
Otolaryngol Suppl, 490:1–10.
Garbag M, Trung Tuong MD, Gros C, et al. 1989. Effects of histamine H3 
receptor ligands on various biochemical indices of histaminergic neuron 
activity in rat brain. Eur J Pharmacol, 164:1–11.Neuropsychiatric Disease and Treatment 2007:3(4) 439
Betahistine for Ménière’s disease
Gustave dit Duﬂ  o S, Gestreau C, Lacour M. 2000. Fos expression in the 
rat brain after exposure to gravito-inertial force changes. Brain Res, 
861:333–44.
Gustave dit Duﬂ  o S, Gestreau C, Tighilet B, et al. 1999. Fos expression 
in the cat brainstem after unilateral vestibular neurectomy. Brain Res, 
824:1–17.
Halmagyi GM, Curthoys IS, Cremer PD, et al. 1990. The human horizontal 
vestibulo-ocular reﬂ  ex in response to high-acceleration stimulation 
before and after unilateral vestibular neurectomy. Exp Brain Res, 
81:479–90.
Havia M, Kentala E. 2004. Progression of symptoms of dizziness in 
Ménière’s disease. Arch Otolaryngol Head Neck Surg, 130:431–5.
Horii A, Takeda N, Matsunaga T, et al. 1993. Effect of unilateral vestibular 
stimulation on histamine release from the hypothalamus of rats in vivo. 
J Neurophysiol, 70:1822–6.
Horii A, Mitani K, Kitahara T, et al. 2004. Paroxetine, a selective 
serotonin reuptake inhibitor, reduces depressive symptoms and 
subjective handicaps in patients with dizziness. Otol Neurotol, 
25:536–43.
Inverarity DJ, Johnston AR, McQueen DS, et al. 1993. Effects of hista-
mine on rat medial vestibular nucleus neurones in vitro. J Physiol, 
459:466.
Jaju B, Wang SC. 1971. Effects of diphenhydramine and dimenhydri-
nate on vestibular neuronal activity of cat: a search for the locus 
of their antimotion sickness action. J Pharmacol Exp Therap, 
176:718–24.
Kentala E. 1996. Characteristics of six otologic diseases involving vertigo. 
Am J Otol, 17:883–92.
Kiang NY. 1990. Curious oddments of auditory-nerve studies. Hear Res, 
49:1–16.
Kingma H, Bonink M, Meulenbroeks, et al. 1997. The dose-dependent 
effect of betahistine on vestibulo-ocular reﬂ  ex: a double-blind, placebo 
controlled study in patients with paroxysmal vertigo. Acta Otolaryngol, 
117:1–6.
Kinney SE, Sandridge SA, Newman CW. 1997. Long-term effects 
of Ménière’s disease on hearing and quality of life. Am J Otol, 
18:67–73.
Klockhoff I, Lindblom U. 1967. Ménière’s disease and hydrochlorothiazide 
(Dichlotride)—a critical analysis of symptoms and therapeutic effects. 
Acta Otolaryngol, 63:347–65.
Kluyskens P, Lambert P, D’Hooge D. 1990 Trimetazidine versus betahis-
tine in vestibular vertigo. A double blind study. Ann Otolaryngol Chir 
Cervicofac, 107(Suppl 1):11–9.
Kotimaki J, Sorri M, Aantaa E, et al. 1999. Prevalence of Ménière disease 
in Finland. Laryngoscope, 109:748–53. 
Lacour M, Borel L. 1993. Vestibular control of posture and gait. Arch Ital 
Biol, 131:81–104.
Lacour M, Sterkers O. 2001. Histamine and betahistine in the treat-
ment of vertigo: elucidation of mechanisms of action. CNS Drugs, 
15:853–70.
Lacour M, Toupet M, Denise P, et al. 1989. Vestibular compensation. Facts, 
theories and clinical perspectives. Paris: Elsevier.
Laurens-Thalen, EO, Wit HP, Segenhout JM, et al. 2004. Direct measure-
ment of the ﬂ  ow resistance of the aqueduct in the guinea pig. Acta 
Otolaryngol, 124:1–5.
Laurikainen EA, Miller JM, Nuttall AL, et al. 1998. The vascular mecha-
nisms of action of betahistine in the inner ear of the guinea pig. Eur 
Arch Otorhinolaryngol, 255:119–23.
Laurikainen EA, Miller JM, Quirk WS, et al. 1993. Betahistine-induced 
vascular effects in the rat cochlea. Am J Otol, 14:24–30.
Lin JS. 1994. Système histaminergique central et états de vigilance chez le 
chat. Thèse Doct Sciences, Université Claude Bernard, Lyon. 
Lopez C, Borel L, Magnan J, et al. 2005. Torsional optokinetic nystagmus 
after unilateral vestibular loss: asymmetry and compensation. Brain, 
In press.
Luxon LM. 1984. The anatomy and physiology of vestibular system. In Dix 
MR, Hood J eds. Vertigo. New York: John Wiley and Sons. p 1–36.
Martini A, De Domenico F. 1990. Trimetazidine versus betahistine in 
Ménière’s disease. A double blind method. Ann Otolaryngol Chir 
Cervicofac, 107(Suppl 1):20–7.
Mira E. 2001. Betahistine in the treatment of vertigo. History and 
clinical implications of recent pharmacological researches. Acta 
Otorhinolaryngol Ital, 21(Suppl 66):1–7.
Mira E, Guidetti G, Ghilardi L, et al. 2003. Betahistine dihydrochloride in the 
treatment of peripheral vestibular vertigo. Eur Arch Otorhinolaryngol, 
260:73–7.
Merchant SN, Adams JC, Nadol JB Jr. 2005. Physiopathology of ménière’s 
syndrome: are symptoms caused by endolymphatic hydrops? Otol 
Neurotol, 26:74–81
Meyer JS, Mathew NT, Hartmann A, et al. 1974. Orally administrated 
betahistine and regional cerebral blood ﬂ  ow in cerebrovascular disease. 
J Clin Pharmacol, 14:280–5.
Novotny M, Kostrica R. 2002. Fixed combination of cinnarizine and dimen-
hydrinate versus betahistine dimesylate in the treatment of Ménière’s 
disease: a randomized, double-blind, parallel group clinical study. Int 
Tinnitus J, 8:115–23.
Oosterveld WJ. 1984. Betahistine dihydrochloride in the treatment of vertigo 
of peripheral vestibular origin. A double-blind placebo-controlled study. 
J Laryngol Otol, 98:37–41.
Oosterveld WJ. 1987. Effect of betahistine dihydrochloride on induced 
vestibular nystagmus: a double blind study. Clin Otolaryngol Allied 
Sci, 12:131–5.
Panula P, Pirvola U, Auvinen S, et al. 1989. Histamine-immunoreactive 
nerve ﬁ  bers in the rat brain. Neuroscience, 28:585–610.
Phelan KD, Nakamura J, Gallagher JP. 1990. Histamine depolarizes rat 
medial vestibular nucleus neurons recorded intracellularly in vitro. 
Neurosci Lett, 109:287–92.
Pollard H, Schwartz JC. 1987. Histamine neuronal pathways and their 
function. Trends Neurosci, 10:86–9.
Pondugula SR, Sanneman JD, Wangemann P, et al. 2004. Glucocorticoids 
stimulate cation absorption by semicircular canal duct epithelium 
via epithelial sodium channel. Am J Physiol Renal Physiol, 286:
F1127–35. 
Rascol O, Hain TC, Brefel C, et al. 1995. Antivertigo medications and 
drug-induced vertigo. Drugs, 50:777–91.
Scholtz AW, Schwarz M, Baumann W, et al. 2004. Treatment of vertigo due 
to acute unilateral vestibular loss with a ﬁ  xed combination of cinnarizine 
and dimenhydrinate: a double-blind, randomized, parallel-group clinical 
study. Clin Ther, 26:866–77.
Schwartz JC. 1979. Histamine receptors in brain. Life Sci, 25:895–912.
Schwartz JC, Arrang JM, Garbarg M, et al. 1990. A third histaminergic 
receptor subtype: characterisation, location and functions of the H3-
receptor. Agents Actions, 30:13–23.
Selmani Z, Marttila T, Pyykkö I. 2005. Incidence of virus infection as 
a cause of Ménière’s disease or endolymphatic hydrops assessed by 
electrocochleography. Eur Arch Otorhinolaryngol, 262:331–4
Seraﬁ  n M, Khateb A, Vibert N, et al. 1993. Medial vestibular nucleus in 
the guinea-pig: histaminergic receptors. I. An in vitro study. Exp Brain 
Res, 93:242–8.
Shojaku H, Watanabe Y. 1997. The prevalence of deﬁ  nite cases of Méniere´s 
disease. Acta Otolaryngol, 528:94–6.
Smith PF, Curthoys IS. 1989. Mechanisms of recovery following 
unilateral labyrinthectomy: a review. Brain Res Brain Res Rev, 
14:155–80.
Smith WK, Sankar V, Pﬂ  eiderer AG. 2005. A national survey amongst 
UK otolaryngologists regarding the treatment of Ménière’s disease. J 
Laryngol Otol, 119:102–5.
Stahle J, Stahle C, Arenberg IK. 1978. Incidence of Ménière’s disease. Arch 
Otolaryngol, 104:99–102.
Stephens SD, Lewis PA, Charny MC, et al. 1990.Characteristics of 
self-reported hearing problems in a community survey. Audiology, 
29:93–100.
Stephens SD, Hogan S, Meredith R. 1991.The desynchrony between complaints 
and signs of vestibular disorders. Acta Otolaryngol, 111:188–92.Neuropsychiatric Disease and Treatment 2007:3(4) 440
Lacour et al
Takeda N, Morita M, Kubo T, et al. 1987. Histaminergic projection from 
the posterior hypothalamus to the medial vestibular nucleus of rats and 
its relation to motion sickness. In Graham MD, Kemink JL eds. The 
vestibular system: Neurophysiologic and clinical research. New York: 
Raven Press. p. 601–17.
Tighilet B, Lacour M. 1996. Distribution of histaminergic axonal ﬁ  bres in 
the vestibular nuclei of the cat. Neuroreport, 7:873–8.
Tighilet B, Lacour M. 1997. Histamine immunoreactivity changes in 
vestibular-lesioned and histaminergic-treated cats. Eur J Pharmacol, 
330:65–77.
Tighilet B, Leonard J, Lacour M. 1995. Betahistine dihydrochloride 
treatment facilitates vestibular compensation in the cat. J Vest Res, 
5:53–66.
Tighilet B, Trottier S, Lacour M. 2005. Dose and duration-dependent effects 
of betahistine dihydrochloride treatment on histamine turnover in the 
cat. Eur J Pharmacol, 523:54–63.
Tighilet B, Trottier S, Mourre C, et al. 2002. Betahistine dihydrochloride 
interaction with the histaminergic system in the cat: neurochemical and 
molecular mechanisms. Eur J Pharmacol, 446:63–73.
Tighilet B, Trottier S, Mourre C, et al. 2006. Changes in histaminergic system 
during vestibular compensation in the cat. J Physiol Lond, In press.
Timmerman H. 1991. Histamine agonists and antagonists. Acta Otolaryngol 
Suppl, 479:5–11.
Tumarkin, A. 1936. The otolythic catastrophe: a new syndrome. BMJ, 
2:175–7.
Van de Heyning PH, Boudewyns A, Wuyts F. 2005. Surgical treatment of 
Ménière’s disease. Curr Opn Neurol, 18:23–28. 
van Deelen GW, Huizing EH. 1986. Use of a diuretic (Dyazide) in the 
treatment of Ménière’s disease. A double-blind cross-over placebo-
controlled study. ORL J Otorhinolaryngol Relat Spec, 48:287–92.
Vibert D, Häusler R. 2000. Long-term evolution of subjective visual vertical 
after vestibular neurectomy and labyrinthectomy. Acta Otolaryngol, 
120:620–2.
Watanabe Y, Mizokoshi K, Shojaku H, et al. 1995. Epidemiological and 
clinical characteristics of Ménière’s disease in Japan. Acta Otolaryngol 
Suppl, 519:206–10. 
Wang JJ, Dutia MB. 1995. Effects of histamine and betahistine on rat 
medial vestibular nucleus neurones: possible mechanism of action of 
anti-histaminergic drugs in vertigo and motion sickness. Exp Brain 
Res, 105:18–24.
Wilson VJ, Melvill Jones G. 1979. Mammalian vestibular physiology. New 
York: Plenum Press. 
Warmerdam T J, Schroder FH, Wit HP, et al. 2003. Perilymphatic and 
endolymphatic pressure during endolymphatic hydrops. Eur Arch 
Otorhinolaryngol, 260:9–11.
Wladislavosky-Waserman P, Facer G, et al. 1984. Ménière´s disease: a 30-
year epidemiologic and clinical study in Rochester, MN, 1951–1980. 
Laryngoscope, 94:1098–02.
Xerri C, Lacour M, 1980. Compensation des déﬁ  cits posturaux et cinétiques 
après neurectomie vestibulaire unilatérale chez le chat. Rôle de l’activité 
sensorimotrice. Acta Otolaryngol, 90:414–20.
Yabe T, de Waele C, Seraﬁ  n M, et al. 1993. Medial vestibular nucleus in 
the guinea-pig: histaminergic receptors. II. An in vivo study. Exp Brain 
Res, 93:249–58.